Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.48 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | IKBKB | O14920 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | CASR | P41180 | 1/20 | 0.40 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | RAF1 | P04049 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13145693 | 0.78 | ALDH1A1 (0.55) | ALDH1A1RECQLSMN1; SMN2POLBTDP1 | |
| SCHEMBL13180244 | 0.77 | ALDH1A1 (0.53) | ALDH1A1RECQLSMN1; SMN2POLBTDP1 | |
| SCHEMBL7654120 | 0.76 | RAF1 (0.63) | RAF1 | |
| SCHEMBL24252069 | 0.75 | NR1H4 (0.59) | ALDH1A1SMN1; SMN2NR1H4 | |
| SCHEMBL31511822 | 0.74 | NR1H4 (0.38) | ALDH1A1SMN1; SMN2LPAR1NR1H4POLB | |
| SCHEMBL5566828 | 0.74 | ALDH1A1 (0.45) | ALDH1A1 | |
| SCHEMBL11204850 | 0.74 | ALDH1A1 (0.49) | ALDH1A1RECQLSMN1; SMN2POLBTDP1 | |
| SCHEMBL3096012 | 0.72 | CA2 (0.50) | ALDH1A1SMN1; SMN2NR1H4TDP1LMNA | |
| SCHEMBL13923626 | 0.70 | SMN1; SMN2 (0.68) | ALDH1A1RECQLSMN1; SMN2LPAR1POLB | |
| SCHEMBL14003501 | 0.70 | ALDH1A1 (1.00) | ALDH1A1RECQLSMN1; SMN2POLBTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100234364-A1 | CCR2 INHIBITORS AND METHODS OF USE THEREOF | CHEMOCENTRYX, INC. | 2010-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234364-A1 | CCR2 INHIBITORS AND METHODS OF USE THEREOF | CCR2, CCR9, CCR1 | ALDH1A1 1572/4885RECQL 4832/4885SMN1; SMN2 1775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.